2024 ASCO® Annual Meeting Insights Hub

Meeting coverage & Vumedi’s exclusive highlights, all in one place.

Skin

5696 views 585 hours watched
05:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Biomarker Analysis & Updated Clinical Outcomes - Neoadjuvant Systemic Treatment With Nivolumab and Relatlimab in Surgically Resectable Melanoma"

FEATURING Liz Burton
  • 134 views
  • July 22, 2024
35:23

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "My Personal Highlights in Melanoma"

FEATURING Sapna Patel
  • 872 views
  • July 11, 2024
  • 4
24:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Melanoma - Neoadjuvant and Adjuvant Treatments, 1L Metastatic & Anti-PD-1 Refractory Disease"

FEATURING Zeynep Eroglu
  • 340 views
  • July 5, 2024
  • 3
11:05

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Highlights in Early Stage, 1L Metastatic, and Refractory Melanoma"

FEATURING Douglas Johnson
  • 556 views
  • June 7, 2024
  • 1
25:29

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Insights in Melanoma"

FEATURING Omid Hamid
  • 492 views
  • June 21, 2024
  • 5
14:46

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Safety & Efficacy of First-in-Class CXCR1/2 Inhibitor SX-682 in Combination With Pembro in Patients With Metastatic Melanoma With Disease Progression on Anti-PD-1 Therapy"

FEATURING Sapna Patel
  • 66 views
  • June 19, 2024
11:27

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Curing Stage IV Melanoma - Where Have We Been and Where Are We"

FEATURING Pippa Corrie
  • 305 views
  • June 20, 2024
  • 1
02:57

ecancer

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi vs. Adjuvant Nivo in Stage III Melanoma"

FEATURING Christian Blank
  • 52 views
  • June 20, 2024
  • 1
15:18

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Adopting Cutting-Edge Cell Therapies in Melanoma"

FEATURING Allison Betof Warner
  • 197 views
  • June 11, 2024
03:12

ecancer

ASCO® 2024 Insights: "PIVOTAL Study - Neoadjuvant Daromun vs. Immediate Surgery in Fully Resectable Melanoma"

FEATURING Axel Hauschild
  • 43 views
  • June 20, 2024
09:13

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "QoL Data With Neoadjuvant Ipi & Nivo in Resectable Stage III Melanoma - 36-Week Data From the NADINA Trial"

FEATURING Judith Lijnsvelt
  • 67 views
  • June 14, 2024
  • 2
03:36

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "PIVOTAL Study - Daromun vs. Immediate Surgery in Resectable Melanoma With Regional Metastases"

FEATURING Axel Hauschild
  • 69 views
  • June 11, 2024
09:54

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-047 Trial 3-Year OS and MSS Outcomes - Nivo + Rela vs. Nivo for Previously Untreated Metastatic/Unresectable Melanoma"

FEATURING Hussein Tawbi
  • 481 views
  • June 12, 2024
  • 1
08:41

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NADINA Trial - Neoadjuvant Nivo + Ipi in Macroscopic, Resectable Stage 3 Melanoma"

FEATURING Christian Blank
  • 293 views
  • June 14, 2024
  • 2
06:48

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "SCOPE Trial - Efficacy & Safety of SCIB1 Vaccine With Nivo & Ipi in Advanced Unresectable Melanoma"

FEATURING Heather Shaw
  • 25 views
  • June 13, 2024
14:01

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Macroscopic Stage III Melanoma and Immunotherapy - Pre-op, Post-op or No-op? NADINA Trial Discussion"

FEATURING Harriet Kluger
  • 131 views
  • June 10, 2024
  • 2
20:16

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "Immunotherapy & Beyond - Advances in Systemic Therapy for Patients With Melanoma and Brain Metastases"

FEATURING Hussein Tawbi
  • 201 views
  • June 12, 2024
  • 2
11:33

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Summary: "PD-1-Refractory Advanced Melanoma - Getting to the Finish Line"

FEATURING Meredith Mckean
  • 153 views
  • June 10, 2024
  • 4
09:25

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "NEO-TIM Trial - Combination or Sequence of Vemurafenib, Cobimetinib, and Atezolizumab in High-Risk Resectable Melanoma"

FEATURING Paolo A. Ascierto
  • 41 views
  • June 12, 2024
09:31

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Roginolisib, an Oral, Highly Selective and Allosteric Modulator of PI3Kd for Uveal Melanoma and Advanced Cancers"

FEATURING Anna Maria Di Giacomo
  • 45 views
  • June 12, 2024
12:22

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "KEYNOTE-942 Trial - 3-Year Update on mRNA-4157 & Pembro in Resected Melanoma"

FEATURING Jeffrey Weber
  • 237 views
  • June 12, 2024
  • 1
11:34

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RELATIVITY-048 Trial - Efficacy and Safety of Triplet Nivo + Rela + Ipi in Advanced Melanoma"

FEATURING Paolo A. Ascierto
  • 207 views
  • June 12, 2024
  • 3
10:17

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "RegoMel Trial - Regorafenib in Patients With Pretreated Advanced Melanoma"

FEATURING Iris Dirven
  • 33 views
  • June 7, 2024
08:10

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "OBX-115, IL2-Sparing Engineered TIL Cell Therapy for Immune Checkpoint Inhibitor-Resistant Unresectable/Metastatic Melanoma"

FEATURING Rodabe Amaria
  • 39 views
  • June 11, 2024
03:55

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "COMBI-AD Study - Dabrafenib + Trametinib in Stage III BRAF-Mutated Melanoma"

FEATURING Axel Hauschild
  • 533 views
  • June 11, 2024
  • 1
01:52

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Individualized Neoantigen Therapy mRNA-4157 (V940) + Pembro in Resected Melanoma"

FEATURING Meredith Mckean
  • 36 views
  • June 11, 2024
07:38

2024 ASCO® Annual Meeting Insights Hub

ASCO® 2024 Insights: "Novel RNA-Nanoparticle Vaccine for the Treatment of Early Melanoma Recurrence Following Adjuvant Anti-PD-1 Antibody Therapy"

FEATURING Bently Doonan
  • 48 views
  • June 6, 2024